Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3

Journal of Virology

Volumn 75, Issue 10, 2001, Pages 4594-4603

  Schmidt, A C ^a   McAuliffe, J M ^a   Murphy, B R ^a   Collins, P L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOMODULATION; NONHUMAN; OPEN READING FRAME; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SYRIAN HAMSTER; VACCINE PRODUCTION; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS RESISTANCE;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BASE SEQUENCE; CATTLE; CELL LINE; CRICETINAE; DNA, VIRAL; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNITY, MUCOSAL; MACACA MULATTA; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; OPEN READING FRAMES; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 3, HUMAN; RECOMBINATION, GENETIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY SYSTEM; RESPIROVIRUS; RESPIROVIRUS INFECTIONS; TUMOR CELLS, CULTURED; VACCINATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 0035037154     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.10.4594-4603.2001     Document Type: Article

References (62)

1. Distinct types of lung disease caused by functional subsets of antiviral T cells
2. A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates
3. Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates
4. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: Effect of mutation upon fusion function
5. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA
6. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees
7. Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers
8. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants
9. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test
10. Biophysical studies of respiratory syncytial virus. I. Density of respiratory syncytial virus and associated complement-fixing antigens in cesium chloride density gradient
11. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: Nucleotide sequence analysis of variants selected with monoclonal antibodies
12. Parainfluenza viruses
13. Respiratory syncytial virus
14. Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virus
15. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics
16. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV
17. + T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies
18. Protection of weanling hamsters from experimental infection with wild-type parainfluenza virus type 3 (para 3) by cold-adapted mutants of para 3
19. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development
20. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates
21. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV
22. Respiratory syncytial virus vaccines
23. Recovery of infectious human parainfluenza virus type 3 from cDNA
24. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy
25. Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein
26. A simian strain of hepatitis A virus, AGM-27, functions as an attenuated vaccine for chimpanzees
27. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys
28. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one
29. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection
30. An update on the "Jennerian" and modified "Jennerian" approach to vaccination of infants and young children against rotavirus diarrhea
31. Respiratory syncytial virus vaccines
32. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant
33. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants
34. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, infants and children
35. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children
36. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children
37. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus
38. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
39. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus
40. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection
41. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses
42. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses
43. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine
44. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization
45. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity
46. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates
47. Bronchiolitis-associated hospitalizations among US children, 1980-1996
48. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children 1979-1997
49. Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes
50. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia
51. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection
52. The attenuation phenotype conferred by the M gene of the influenza A/Ann Arbor/6/60 cold-adapted virus (H2N2) on the A/Korea/82 (H3N2) reassortant virus results from a gene constellation effect
53. Are there alternative avian influenza viruses for generation of stable attenuated avian-human influenza A reassortant viruses?
54. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3
55. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates
56. 3 is essential for replication
57. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge
58. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV
59. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity
60. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children
61. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy
62. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells